CORONA Remedies IPO

CORONA Remedies is one of the fastest climbers in India’s pharma space, the second fastest-growing company among the top 30 players in the Indian Pharmaceutical Market (IPM). Its domestic sales grew at 16.77% CAGR between June 2022 and June 2025, well ahead of the IPM’s average growth of 9.21%. This strong momentum helped it move up the ranks from 37th to 29th place nationally.

Its gross profit margin rose from 76.14% in FY23 to 80.23% in FY25, while the EBITDA margin (which measures operating profit) improved from 15.27% to 20.55% in the same time. That’s a sign of tighter cost control and smart expense management alongside rising sales.

Most of CORONA’s portfolio leans toward chronic and sub-chronic segments - long-term treatment areas like diabetes, heart ailments, and women’s health. These accounted for 70.1% of its domestic sales in June 2025, growing at a fast 20.48% CAGR since June 2022. For context, the IPM’s own chronic segment grew about 10%, meaning the company is gaining share in a high-value space.

The company’s Return on Capital Employed (RoCE) improved from 28.36% in FY23 to 41.32% in FY25, and the adjusted RoCE (which factors in one-time effects) stood even higher at 47.87%. In short, the company is squeezing more profit out of every rupee invested.

The company’s sales are minimally affected by mandatory price controls under the National List of Essential Medicines (NLEM); only 9.76% of its total sales in June 2025 fall under this list. That’s much lower than the IPM average of 17.51%, giving it more freedom to set product prices and maintain healthy margins.

The company has a knack for turning new product ideas into successful brands. Of all the products it launched after June 2022, 14.43% crossed ₹5 crore in sales by June 2025, a big lead over the IPM’s average success rate of 5.6%.

The company runs a lean operation. Its net working capital days were only 24.17 in FY25, meaning it recovers cash from sales quickly instead of locking it in inventory or receivables. That discipline keeps cash flow healthy.

Almost all of CORONA Remedies’ business comes from India. In FY25, 96.33% of its total revenue (₹1,152.46 crore) was domestic. This focus has worked well so far, but it also means the company is vulnerable; if local demand slows or if its international growth plans don’t pick up, performance could take a noticeable hit.

Even within India, a large chunk of its sales comes from a few states. As of June 2025, 47.3% of domestic sales came from just five regions - Gujarat, Maharashtra, Chhattisgarh, Goa, and Madhya Pradesh. Any major economic or regulatory change in these markets could directly affect its overall revenue.

The company leans heavily on a limited set of products. Its 27 core “engine” brands made up over 72% of domestic sales (MAT June 2025), and just three treatment areas - women’s healthcare, cardio-diabetic care, and pain management - brought in 62.4% of total revenue (₹746.55 crore) in FY25. This concentration means any slowdown in these products or segments could noticeably dent growth.

The IPO is structured entirely as an Offer for Sale worth ₹655.37 crore, meaning only existing shareholders are selling their stakes. The company won’t receive any money from it, so there’s no fresh capital for operations, expansion, or debt repayment.

Its main plant in Bhayla is already stretched close to its limit. The tablet and capsule manufacturing lines ran at 93.6% utilization in FY25, leaving very little buffer to handle sudden demand spikes or scale up production without investing in new capacity.

The company’s distribution network leans on a handful of major partners. Its five largest C&F agents (carrying and forwarding agents) generated 44.35% of revenue in FY25, over ₹530.6 crore. Any disruption or exit by one of these agents could cause immediate bottlenecks in product distribution.